Terms

Welcome to our website. Nothing on the website constitutes or should be interpreted as medical advice; if you need medical advice please consult your doctor.If you continue to browse and use this website you are agreeing to comply with and be bound by the following terms and conditions of use in relation to this website.The term ‘Autifony Therapeutics’ or ‘us’ or ‘we’ refers to the owner of the website whose registered office is Imperial College Incubator, Level 1 Bessemer Building, Imperial College London, SW7 2AZ, UK. The term ‘you’ refers to the user or viewer of our website.The use of this website is subject to the following terms of use:

  • The content of the pages of this website is for your general information and use only. It is subject to change without notice.
  • Neither we nor any third parties provide any warranty or guarantee as to the accuracy, timeliness, performance, completeness or suitability of the information and materials found or offered on this website for any particular purpose. You acknowledge that such information and materials may contain inaccuracies or errors and we expressly exclude liability for any such inaccuracies or errors to the fullest extent permitted by law.
  • Your use of any information or materials on this website is entirely at your own risk, for which we shall not be liable. It shall be your own responsibility to ensure that any products, services or information available through this website meet your specific requirements.
  • This website contains material which is owned by or licensed to us. This material includes, but is not limited to, the design, layout, look, appearance and graphics. Reproduction is prohibited other than in accordance with the copyright notice, which forms part of these terms and conditions.
  • All trade marks reproduced in this website which are not the property of, or licensed to, the operator are acknowledged on the website.
  • Unauthorised use of this website may give rise to a claim for damages and/or be a criminal offence.
  • From time to time this website may also include links to other websites. These links are provided for your convenience to provide further information. They do not signify that we endorse the website(s). We have no responsibility for the content of the linked website(s).
  • You may not create a link to this website from another website or document without Autifony Therapeutics prior written consent.
  • Your use of this website and any dispute arising out of such use of the website is subject to the laws of the United Kingdom.

Related News

18Dec

Autifony Therapeutics and Boehringer Ingelheim collaborate on a novel therapeutic approach to a range of CNS disorders

0 Comments
Collaboration with funding of development activities gives Boehringer Ingelheim exclusive option to purchase certain Autifony assets to treat serious CNS... Read More →
10Jul

Autifony Therapeutics receives Orphan Drug Designation for AUT00206 for Fragile X Syndrome

0 Comments
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous... Read More →
18May

Autifony Therapeutics initiates recruitment into schizophrenia clinical trial for first-in-class drug

0 Comments
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous... Read More →
15Mar

Autifony Therapeutics obtains £1.3 million in funding from Innovate UK and the Dementia Discovery Fund to explore novel approach to treatment of dementia

0 Comments
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous... Read More →
10Jan

Autifony Therapeutics announces positive results from Phase I study of AUT00206, a first-in-class Kv3 modulator for treatment of schizophrenia

0 Comments
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous... Read More →

Tweets

AutifonyLtd @AutifonyLtd
Autifony Therapeutic  @AutifonyLtd
Autifony is currently recruiting a Junior Medicinal Chemist, the position will be based in our lab in Stevenage, fo… https://t.co/PkP9TCxUcq 
Autifony Therapeutic  @AutifonyLtd
RT @BIODeutschland:Boehringer Ingelheim & Autifony Therapeutics collaborate on a novel therapeutic approach to a range of CNS disorder… https://t.co/sIz3B7CkOe 

Back to Top
Responsive Menu Pro Image Responsive Menu Clicked Image